Is Saxenda the Same as Wegovy? What the Differences Actually Mean

Step 1: Understand what each medicine actually contains

The shortest answer to whether Saxenda and Wegovy are the same is no, and the reason starts with their active ingredients. Saxenda contains liraglutide, manufactured by Novo Nordisk. Wegovy contains semaglutide, also made by Novo Nordisk. Both belong to a class of medicines called GLP-1 receptor agonists, meaning they mimic the hormone GLP-1 to reduce appetite and slow the movement of food through the stomach. That shared mechanism is almost certainly why people assume they are interchangeable — they are not.

Liraglutide was the earlier medicine, approved for weight management in the UK as Saxenda before semaglutide existed in this form. Semaglutide is a later, structurally different molecule with a longer half-life, which is precisely why Wegovy can be injected once a week while Saxenda requires a daily injection. The dosing frequency difference is not a trivial detail; for many people it shapes whether they can stick to treatment at all.

It is also worth saying plainly: Saxenda is not the same as semaglutide. Semaglutide is the ingredient in Wegovy (and in Ozempic, which is licensed for type 2 diabetes rather than weight loss). Liraglutide is the ingredient in Saxenda (and in Victoza, also a diabetes medicine). The two molecules are related by class but not by chemistry, and they are not substitutes for one another clinically.

Step 2: Compare the evidence on how much weight each produces

This is where the gap between the two medicines becomes significant. In the STEP 1 trial, adults taking semaglutide 2.4mg (Wegovy) lost around 15% of their body weight on average over 68 weeks alongside lifestyle changes, as published in the New England Journal of Medicine. Trials of liraglutide 3mg (Saxenda) over comparable periods showed average losses closer to 5–8% of body weight. The difference is substantial enough that it influenced clinical guidelines and the shift in prescribing practice toward semaglutide over recent years.

For anyone weighing up Saxenda and Wegovy directly, the evidence consistently favours semaglutide on average weight reduction. That said, averages describe populations, not individuals. A prescriber will always look at the whole picture, including your medical history, any conditions you have, and which treatment you are most likely to take consistently.

A common misconception is that because Saxenda came first and was widely prescribed, it must be the more established or better-understood option. In reality, semaglutide now has a broader evidence base, higher average efficacy, and updated NICE guidance supporting its use. The older medicine is not the safer or more proven one in this case.

Step 3: Know what's actually licensed for weight loss in the UK right now

Both Saxenda and Wegovy hold UK licences for weight management in adults. Saxenda (liraglutide 3mg) is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. Wegovy (semaglutide 2.4mg, and now also the 7.2mg dose approved by the MHRA in 2026) carries the same broad eligibility criteria. Wegovy's full UK licensing background covers both the injection and, as of June 2026, the first oral GLP-1 tablet licensed for weight management in the UK.

It is also worth noting that Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist made by Eli Lilly, is the other major weight-loss injection available in the UK. If you are exploring all your options, the treatment overview at nume covers how these medicines compare at a practical level.

Saxenda is not a medicine nume dispenses. Our prescribers work with Wegovy and Mounjaro, both of which are licensed for weight management and reviewed by a GPhC-registered Independent Prescriber before any treatment is issued. If you're asking whether Saxenda might suit you better than Wegovy, the evidence-based comparison page goes into that in more depth, and for a side-by-side look at tolerability and results, the head-to-head assessment is a useful read.

Step 4: Consider cost and access in context

Saxenda and Wegovy are both prescription-only medicines. Neither can be legally supplied in the UK without a valid prescription following clinical assessment. Prices for private treatment vary by provider and dose. For context on what Wegovy typically costs through a regulated UK pharmacy, the cost guide for Wegovy in the UK sets out the market picture honestly, including what headline prices often leave out. It is also worth knowing that some side effects are specific to GLP-1 medicines in general rather than to one medicine in particular, so switching from Saxenda to Wegovy does not necessarily mean escaping GI symptoms.

If you are currently on Saxenda and wondering whether Wegovy might be appropriate for you, that is a question for a prescriber rather than a product comparison page. A clinician will look at your response to liraglutide, your current dose, and your overall health before recommending any change. You can start that conversation through a free consultation with our clinical team, who review every case personally before any prescription is issued.